期刊
BLOOD
卷 125, 期 12, 页码 1847-1848出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2015-02-625251
关键词
-
类别
In this issue of Blood, Duvic et al demonstrate that mogamulizumab, a humanized monoclonal antibody targeting the chemokine receptor CCR4, is well tolerated and has significant clinical activity (overall response rate 36.8%, median duration of response 10.4 months) in heavily pretreated patients with mycosis fungoides (MF) and Sezary syndrome (SS).1
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据